Is There an Ozempic Shortage in 2026? The Current Supply Picture

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited

Key Takeaways

• The FDA removed semaglutide from the Drug Shortages Database on February 21, 2025. As of May 2026, no active shortage is listed.
• The shortage that began in early 2022 was driven by fill-finish capacity, not active ingredient supply. Adding pen-assembly capacity took multiple years.
• Novo Nordisk announced major capacity expansions through 2023 and 2024 in Kalundborg (Denmark), Chartres (France), and Clayton (North Carolina), and Novo Holdings completed its acquisition of Catalent at the end of 2024.
• The end of the shortage substantially narrowed the FDA-recognized basis for broad compounding of semaglutide under section 503A.
• Local pharmacy-level supply issues can still happen, but the national shortage status is resolved.

Direct answer

No national Ozempic shortage is listed by the FDA as of May 2026. The FDA Drug Shortages Database removed semaglutide injection on February 21, 2025, after Novo Nordisk demonstrated sustained production capable of meeting demand. Localized supply variation at individual pharmacies can still occur, but the multi-year shortage that began in 2022 is no longer in effect.

Table of contents

1. The current FDA status
2. The full shortage timeline (2022 to 2025)
3. Why the shortage happened
4. What changed to resolve it
5. What "shortage resolved" actually means at the pharmacy counter
6. How the compounding landscape shifted after resolution
7. What could cause a future shortage
8. How to verify current supply yourself
9. What this means for patients
10. FAQ
11. Sources

The current FDA status

The FDA Drug Shortages Database is the authoritative public source for shortage information. As of May 2026, semaglutide injection is not listed. The database shows the resolution date as February 21, 2025, with all doses (Ozempic 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg; Wegovy 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) marked as available.

Wegovy and Ozempic share the same active ingredient and the same FDA shortage classification. When semaglutide was removed from the shortage list, both brands were affected.

The full shortage timeline (2022 to 2025)

Date	Event
March 2022	Novo Nordisk reported supply constraints for Wegovy; FDA shortage listing followed.
August 2022	Ozempic added to the FDA shortage list as off-label weight-loss prescribing surged.
2023	Compounded semaglutide proliferated through telehealth platforms under shortage-tolerance rules; Novo Nordisk announced capacity expansion at Kalundborg and Clayton.
September 2023	FDA added ileus as a postmarketing adverse reaction to the semaglutide label, separate from the shortage issue.
October 2024	Tirzepatide (Mounjaro, Zepbound) removed from the FDA shortage list, foreshadowing semaglutide resolution.
December 2024	Novo Holdings completed its acquisition of Catalent, adding fill-finish capacity.
February 21, 2025	FDA removed semaglutide injection from the shortage list.
March-April 2025	Transition period for compounding; some state-licensed compounding pharmacies wound down semaglutide preparation.
May 2026	Supply stable; no national shortage in effect.

Why the shortage happened

Several forces compounded.

Force 1: Wegovy approval (June 2021) added obesity demand. The same molecule that had been selling steadily for diabetes since 2017 suddenly had a new patient population, often prescribed at higher doses.

Force 2: Off-label prescribing of Ozempic for weight loss exploded. Clinicians prescribed Ozempic off-label for patients without diabetes, drawing supply away from diabetes patients who depended on it.

Force 3: Social-media virality accelerated demand. The semaglutide story moved through TikTok, Twitter, and traditional media in 2022 and 2023, expanding awareness beyond the population that meets clinical criteria.

Force 4: Fill-finish capacity could not scale fast. The bottleneck was pen assembly. Adding fill-finish capacity required years of build-out and regulatory qualification.

The active ingredient itself, semaglutide drug substance, was not the limiting factor. Novo Nordisk's Kalundborg API plant produced enough drug substance to support production growth before fill-finish capacity could catch up. The mismatch between API capacity and fill-finish capacity drove the prolonged shortage.

What changed to resolve it

The resolution had three pillars.

Pillar 1: Novo Nordisk built capacity. The Clayton, North Carolina facility added fill-finish lines through 2023 and 2024. Chartres in France expanded. Kalundborg continued to grow.

Pillar 2: Novo Holdings acquired Catalent. The December 2024 close of the Catalent acquisition gave Novo Holdings (and through it, Novo Nordisk) access to substantial additional fill-finish capacity that could be deployed for semaglutide production.

Pillar 3: Demand stabilized. After the initial surge, demand growth moderated as cash-pay markets saturated, payer coverage decisions stabilized, and the novelty factor declined. The capacity-to-demand ratio improved from both sides.

By early 2025, Novo Nordisk could demonstrate to the FDA that production was sustainably meeting demand across all dose strengths. The FDA then resolved the shortage classification on February 21, 2025.

What "shortage resolved" actually means at the pharmacy counter

Resolution at the FDA level means the agency no longer considers the supply situation a shortage. It does not mean every pharmacy has every dose in stock on every day.

Patients may still encounter:

• Periodic stock-outs at individual pharmacies that can be resolved by transfer to another pharmacy in the area.
• Specific NDC codes (particular dose and pen configurations) being temporarily unavailable.
• Distribution-level delays of a few days for specific lot codes.
• Pharmacy-level prioritization of patients with existing prescriptions over new starters during transition periods.

These pharmacy-level fluctuations are part of normal pharmaceutical distribution and do not reflect a national shortage.

How the compounding landscape shifted after resolution

Compounded semaglutide became widely available during the shortage period because FDCA section 503A allows state-licensed compounding pharmacies to compound drugs that are on the FDA shortage list, in response to individual prescriptions.

The February 2025 resolution narrowed that basis.

• Compounding under the "essentially a copy of an FDA-approved drug" exemption became substantially restricted.
• Compounding pharmacies and telehealth platforms that had built businesses on shortage-tolerance compounding wound down or restructured.
• Novo Nordisk pursued litigation against entities the company alleged continued to market compounded semaglutide as equivalent to Ozempic or Wegovy.
• Some clinically specific compounding (such as preparation with a different active ingredient or formulation that addressed an individual patient's documented clinical need) remained possible under narrower rules.

Patients who had been receiving compounded semaglutide during the shortage often transitioned to brand-name Ozempic or Wegovy, switched to tirzepatide (Mounjaro or Zepbound), or discontinued therapy.

What could cause a future shortage

Several scenarios could push semaglutide back to the shortage list.

1. New indications that materially expand demand. Approvals for additional cardiovascular, renal, or other indications could draw substantial new prescribing.
2. Major payer policy shifts. Expanded Medicare or commercial coverage could pull large patient populations into the market on short timelines.
3. A manufacturing disruption. An incident at Kalundborg, Clayton, or another major site could constrain output regionally or globally.
4. A regulatory finding. An FDA inspection or compliance issue at a key facility could pause production temporarily.
5. Geopolitical or trade events. Disruption to shipping lanes between API sites and fill-finish sites could create timing-driven shortages.

None of these are predicted, but each is plausible enough that "shortage cannot happen again" would be overconfident.

How to verify current supply yourself

The best sources for live information are direct.

• FDA Drug Shortages Database. Available at the FDA website; updated as manufacturers report changes.
• American Society of Health-System Pharmacists (ASHP) Drug Shortages list. A parallel professional resource that sometimes reflects pharmacy-level perspective.
• Your pharmacy. Pharmacy staff can check distributor inventory for specific NDCs in real time, often more accurately than national lists.
• Novo Nordisk's supply update page. The manufacturer occasionally publishes supply status communications.

News coverage often lags real-time data. A pharmacy check is more reliable than a headline.

What this means for patients

The practical implications:

• If your prescription has been on hold or you have been waiting for supply, supply is now generally available. Confirm with your pharmacy.
• If you have been on compounded semaglutide, discuss with your clinician whether to transition to brand-name therapy.
• If you were considering starting Ozempic or Wegovy, supply availability is no longer a major barrier; coverage and cost remain the principal constraints.
• If you experience a pharmacy-level stock-out, check with another local pharmacy or your wholesaler-affiliated network before assuming a broader shortage.

The contrary view: why "resolved" is not "abundant"

A balanced reading acknowledges that "no shortage" is not the same as "easy access."

• Coverage is uneven. Insurance coverage of Wegovy varies; many patients without coverage cannot afford cash list prices.
• Capacity has limits. Demand growth at historical rates could outpace capacity again over a few years.
• Manufacturing concentration is high. Two companies (Novo Nordisk and Eli Lilly) supply the entire US GLP-1 market. Concentration creates systemic risk.
• Global supply is uneven. Markets outside the United States and Europe have experienced delayed access; "resolved" status applies to specific markets and may not be globally uniform.

Calling the shortage over is correct. Calling supply abundant is not. The right framing is "supply is meeting current demand under current coverage."

FAQ

Is there an Ozempic shortage in 2026?

No national shortage is listed by the FDA. Local pharmacy-level supply variation can occur but is not a shortage.

When did the FDA officially end the Ozempic shortage?

February 21, 2025.

What caused the original shortage?

Demand growth from Wegovy approval and off-label Ozempic prescribing outpaced fill-finish capacity.

Has Wegovy supply also recovered?

Yes. Wegovy shares the semaglutide shortage classification with Ozempic. Both are listed as resolved.

Should I still be on compounded semaglutide?

Discuss with your prescribing clinician. The shortage-tolerance basis for compounding narrowed after February 2025.

Can I check live supply online?

The FDA Drug Shortages Database is the official source. Your pharmacy can check distributor-level stock for specific NDCs.

Will another shortage happen?

Possible but not predicted. Capacity has expanded; demand growth has moderated. The risk is lower than it was in 2022-2024.

Does the shortage end affect prices?

No direct mechanism. List prices are set by the manufacturer and not driven by shortage status. Coverage and rebate dynamics are the larger price levers.

Related guides

• Is There a Zepbound Shortage in 2026? Where Tirzepatide Supply Stands
• The GLP-1 Supply Chain Explained: How the Shortage Happened, What Fixed It, What Compounding Did
• Is Ozempic Safe Long-Term? The Honest Answer From the Current Evidence Base
• Where Is Ozempic Manufactured? Mapping Novo Nordisk's Global Supply Chain

Sources

1. US Food and Drug Administration. Drug Shortages Database. Semaglutide injection resolution, February 21, 2025.
2. US Food and Drug Administration. Drug Shortages Database. Tirzepatide injection resolution, October 2, 2024.
3. Federal Food, Drug, and Cosmetic Act. Section 503A (compounding by licensed pharmacists).
4. Novo Nordisk A/S. Annual Report 2024. Capacity disclosures.
5. Novo Holdings. Catalent acquisition completion announcement, December 2024.
6. American Society of Health-System Pharmacists. Drug Shortages Resource Center.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. US Food and Drug Administration. Ozempic and Wegovy Prescribing Information.
10. FDA. Guidance for Industry: Compounding Animal and Human Drugs Under Section 503A of the FD&C Act. Current edition.

Footer disclaimers

Platform Disclaimer. FormBlends provides general educational content about drug supply status. Live shortage status should be verified through the FDA Drug Shortages Database. This article is not a substitute for clinical care.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. After the February 2025 resolution of the semaglutide shortage, the legal and regulatory basis for compounding under FDCA section 503A narrowed substantially.

Results Disclaimer. Supply status applies to the national availability of FDA-approved products. Pharmacy-level availability and individual patient experience may differ from national status.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with either manufacturer.